Call it a big day for Roche at the FDA, as the drug giant picked up two critical approvals on Thursday, first for hemophilia A drug Hemlibra and then with a label expansion for Gazyva. More: Roche nabs blockbuster FDA
read moreAstellas has joined the biopharma who’s who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs. In a legal filing, the drugmaker disclosed a federal subpoena for information about its contributions, as part
read moreAmid allegations about price hikes on key insulin products Humulin and Humalog, Eli Lilly is facing a lawsuit claiming it ran a “multi-tiered kickback scheme” to pump up sales of the same drugs. More: Lilly used nursing services as kickbacks
read morePfizer’s Ibrance had a big head start on Novartis rival Kisqali in the U.S., but when it comes to England, new discount deals with cost-effectiveness watchdogs have the contenders on more equal footing. More: Pfizer's Ibrance, Novartis' Kisqali go to
read moreHere’s your pharma manufacturing news of note. More: News of Note—Sun Pharma’s U.S. sales crash; Avista expands API capacity; Quotient Sciences buys CDMO Source: fierce
read moreTakeda’s Adcetris could soon be on the market in Europe as a second-line treatment for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after regulatory advisors backed expanding the drug’s scope. More: EU advisors back expanding use of Adcetris Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals